Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High Risk Smoldering Multiple Myeloma”

44 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 44 results

Large-scale testing (Phase 3)Looking for participantsNCT07393282
What this trial is testing

Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

Who this might be right for
High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals 270
Testing effectiveness (Phase 2)Active Not RecruitingNCT04933539
What this trial is testing

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT05955508
What this trial is testing

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma (SMM)
Regeneron Pharmaceuticals 40
Early research (Phase 1)Looking for participantsNCT05055063
What this trial is testing

With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01441973
What this trial is testing

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Bristol-Myers Squibb 41
Testing effectiveness (Phase 2)WithdrawnNCT01660997
What this trial is testing

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT03850522
What this trial is testing

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Lene Meldgaard Knudsen 6
Early research (Phase 1)Study completedNCT02697383
What this trial is testing

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Who this might be right for
Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Looking for participantsNCT04776395
What this trial is testing

Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Plasma Cell Myeloma
Emory University 68
Large-scale testing (Phase 3)Study completedNCT00480363
What this trial is testing

QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT02960555
What this trial is testing

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

Who this might be right for
Smoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center 61
Early research (Phase 1)Study completedNCT02492750
What this trial is testing

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

Who this might be right for
Indolent Plasma Cell MyelomaPlasma Cell MyelomaSmoldering Plasma Cell Myeloma
Mayo Clinic 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT02415413
What this trial is testing

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
PETHEMA Foundation 90
Testing effectiveness (Phase 2)Looking for participantsNCT06140524
What this trial is testing

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)
Regeneron Pharmaceuticals 116
Testing effectiveness (Phase 2)Active Not RecruitingNCT03289299
What this trial is testing

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Who this might be right for
Smoldering Multiple Myeloma
International Myeloma Foundation 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT05767359
What this trial is testing

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Dana-Farber Cancer Institute 20
Large-scale testing (Phase 3)Active Not RecruitingNCT01169337
What this trial is testing

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Who this might be right for
Light Chain Deposition DiseaseSmoldering Multiple Myeloma
National Cancer Institute (NCI) 226
Testing effectiveness (Phase 2)Study completedNCT01484275
What this trial is testing

Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Who this might be right for
High-risk Smoldering Multiple Myeloma
Janssen Research & Development, LLC 85
Testing effectiveness (Phase 2)Active Not RecruitingNCT03236428
What this trial is testing

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal GammopathySmoldering Multiple Myeloma
Dana-Farber Cancer Institute 42
Large-scale testing (Phase 3)Study completedNCT03301220
What this trial is testing

Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Janssen Research & Development, LLC 390
Next Page